Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

BACKGROUND: SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting neutralising IgG and specific T-cell response. A third heterologous dose of SOBERANA-Plus (RBD-dimer) further increased neutr...

Descripción completa

Detalles Bibliográficos
Autores principales: Toledo-Romaní, María Eugenia, García-Carmenate, Mayra, Valenzuela-Silva, Carmen, Baldoquín-Rodríguez, Waldemar, Martínez-Pérez, Marisel, Rodríguez-González, Meiby, Paredes-Moreno, Beatriz, Mendoza-Hernández, Ivis, González-Mujica Romero, Raúl, Samón-Tabio, Oscar, Velazco-Villares, Pablo, Bacallao-Castillo, Juan Pablo, Licea-Martín, Ernesto, Rodríguez-Ortega, Misladys, Herrera-Marrero, Nuris, Caballero-González, Esperanza, Egües-Torres, Liudmila, Duartes-González, Reinaldo, García-Blanco, Serguey, Pérez-Cabrera, Suzette, Huete-Ferreira, Santos, Idalmis-Cisnero, Kirenia, Fonte-Galindo, Omayda, Meliá-Pérez, Dania, Rojas-Remedios, Ivonne, Doroud, Delaram, Gouya, Mohammad Mehdi, Biglari, Alireza, Fernández-Castillo, Sonsire, Climent-Ruiz, Yanet, Valdes-Balbín, Yury, García-Rivera, Dagmar, Van der Stuyft, Patrick, Verez-Bencomo, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803910/
https://www.ncbi.nlm.nih.gov/pubmed/36618081
http://dx.doi.org/10.1016/j.lana.2022.100423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803910/
https://www.ncbi.nlm.nih.gov/pubmed/36618081
http://dx.doi.org/10.1016/j.lana.2022.100423

Ejemplares similares